Sociedad Americana de Hirudoterapia

American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients.

Research article published in Blood advances (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Practice guidelineEnsayos clínicosDesarrollo de fármacosMonagle et al. · Blood advances, 2025

Abstract

BACKGROUND: The American Society of Hematology (ASH) guidelines on treatment of pediatric venous thromboembolism (VTE) were published in 2018. In the last 6 years, there has been a 10-fold increase in the number of children involved in VTE treatment trials. OBJECTIVE: The ASH Committee on Quality and Guidelines agreed to update the pediatric guidelines in conjunction with the International Society on Thrombosis and Haemostasis (ISTH). These ASH/ISTH evidence-based guidelines are intended to support patients, clinicians, and other health care professionals in the management of pediatric patients with VTE. METHODS: ASH/ISTH formed a multidisciplinary guideline panel to minimize potential bias from conflicts of interest. An unconflicted patient representative was not identified. The University of Kansas Health System supported the guideline development process, updating or performing systematic evidence reviews up to 2024. The panel focused specifically on the 2018 questions for which there was the greatest amount of interim data. The panel used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 20 recommendations and also provided implementation guidance on the optimal use of anticoagulants in pediatric patients. Key recommendations of these guidelines include the role of DOACs in the treatment of a variety of pediatric VTEs. CONCLUSIONS: Further research is required. Key priorities are understanding the natural history of clinically unsuspected thrombosis across a range of patient subpopulations and obtaining real-world data on the use of DOACs in children.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticlePractice Guideline
Indexed MeSH termsHumansVenous ThromboembolismChildAnticoagulantsSocieties, MedicalHematologyUnited StatesHemostasis

Resumen

The American Society of Hematology (ASH) guidelines on treatment of pediatric venous thromboembolism (VTE) were published in 2018. In the last 6 years, there has been a 10-fold increase in the number of children involved in VTE treatment trials.

Por qué esto importa para la hirudoterapia

Este artículo presenta las directrices actualizadas de 2024 ASH/ISTH basadas en la evidencia para el tratamiento de la enfermedad tromboembólica venosa (ETV) en pacientes pediátricos, emitiendo 20 recomendaciones, incluido el papel de los anticoagulantes orales directos (DOACs) en diversos escenarios de ETV pediátrica. Las directrices abordan la farmacoterapia anticoagulante, pero no mencionan la hirudoterapia, los agentes derivados de la sanguijuela (por ejemplo, hirudina, lepirudina, bivalirudina) ni el secretoma de la sanguijuela. Si bien el tema del manejo de la trombosis se solapa ampliamente con el espacio terapéutico en el que los anticoagulantes derivados de la sanguijuela han funcionado históricamente, no existe ninguna conexión directa o indirecta con la sanguijuela expuesta en el resumen. La relevancia para la hirudoterapia es insignificante basándose únicamente en este resumen.

Citación

American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients.

Monagle et al. · Blood advances, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.